Cartesian Therapeutics (RNAC) Leases (2018 - 2025)
Cartesian Therapeutics (RNAC) has disclosed Leases for 8 consecutive years, with $5.6 million as the latest value for Q4 2025.
- On a quarterly basis, Leases rose 1.19% to $5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.6 million, a 1.19% increase, with the full-year FY2025 number at $5.6 million, up 1.19% from a year prior.
- Leases was $5.6 million for Q4 2025 at Cartesian Therapeutics, up from $5.0 million in the prior quarter.
- In the past five years, Leases ranged from a high of $13.9 million in Q2 2024 to a low of $3.2 million in Q4 2022.
- A 5-year average of $9.0 million and a median of $9.9 million in 2021 define the central range for Leases.
- Peak YoY movement for Leases: crashed 67.44% in 2022, then soared 214.63% in 2023.
- Cartesian Therapeutics' Leases stood at $9.8 million in 2021, then plummeted by 67.44% to $3.2 million in 2022, then skyrocketed by 214.63% to $10.1 million in 2023, then tumbled by 45.02% to $5.5 million in 2024, then grew by 1.19% to $5.6 million in 2025.
- Per Business Quant, the three most recent readings for RNAC's Leases are $5.6 million (Q4 2025), $5.0 million (Q3 2025), and $5.2 million (Q2 2025).